Pipeline
We are building a diverse pipeline of novel immunometabolic modulators.
At the core of our discovery engine lies a “specialized” library of small molecules uniquely designed to engage with lipid-binding proteins. Our profound understanding of lipid biology and the mechanisms by which our specialized drugs interacts with their target proteins to modulate immune cell metabolism guide our development efforts.
Discovery: Identify lead compounds that selectively engage with the biological target and influence its function in cells
In vivo proof-of concept (POC): Establish disease modifying activity of the drug candidates in relevant animal models
Lead optimization: Optimize efficacy, pharmacokinetic and toxicokinetic parameters
Investigational new drug (IND)-enabling: Perform studies required by the regulator authorities for initiating human clinical trials
*In combination with immunotherapy
1
2
3
4